GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -121.25% | -119.53% | 244.52% | 247.40% | -30.65% |
| Total Other Revenue | -56.09% | -59.61% | -9.73% | -7.96% | -45.64% |
| Total Revenue | -97.08% | -97.30% | 258.13% | 265.26% | -37.09% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -97.08% | -97.30% | 258.13% | 265.26% | -37.09% |
| SG&A Expenses | -5.31% | -12.95% | -41.67% | -40.50% | -64.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.04% | -27.40% | -28.28% | -26.84% | -54.42% |
| Operating Income | 3.29% | 11.09% | 33.91% | 32.58% | 57.17% |
| Income Before Tax | -25.89% | -15.74% | 43.50% | 42.36% | 51.69% |
| Income Tax Expenses | -288.89% | -274.07% | 872.73% | 900.00% | 145.45% |
| Earnings from Continuing Operations | -25.62% | -15.49% | 43.38% | 42.24% | 51.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.62% | -15.49% | 43.38% | 42.24% | 51.66% |
| EBIT | 3.29% | 11.09% | 33.91% | 32.58% | 57.17% |
| EBITDA | -3.59% | 4.77% | 25.73% | 24.23% | 58.91% |
| EPS Basic | 18.95% | 25.52% | 73.65% | 73.16% | 73.07% |
| Normalized Basic EPS | 18.57% | 25.42% | 73.76% | 73.20% | 73.10% |
| EPS Diluted | 18.95% | 25.52% | 73.65% | 73.16% | 73.07% |
| Normalized Diluted EPS | 18.57% | 25.42% | 73.76% | 73.20% | 73.10% |
| Average Basic Shares Outstanding | 55.01% | 55.01% | 115.12% | 115.12% | 79.29% |
| Average Diluted Shares Outstanding | 55.01% | 55.01% | 115.12% | 115.12% | 79.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |